#### ADM TRONICS UNLIMITED INC/DE

Form 10KSB/A January 27, 2006

> SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > FORM 10-KSB/A (Amendment No. 2)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended March 31, 2005

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ( ) EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_ to

Commission file number: 1-17629

ADM TRONICS UNLIMITED, INC. (Name of Small Business Issuer in its Charter)

Delaware (State or Other Jurisdiction (I.R.S. Employer of Incorporation or Organization) Identification No.)

22-1896032

224-S Pegasus Avenue, Northvale, New Jersey 07647 (Address of Principal Executive Offices) (Zip Code)

> (201) 767-6040 (Issuer's Telephone Number)

Securities registered pursuant to Section 12(b) of the Act:

None

Title of Each Class Name of Each Exchange on which Registered None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, \$.0005 par value (Title of Class)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES[X] NO[\_]

Check if there is no disclosure of delinquent filers pursuant to Item 405 of Regulation S-B contained in the form, and no disclosure will be contained, to the best of the issuer's knowledge, in definitive proxy or information

statements incorporated by reference in Part III of the Form 10-KSB. [X]

The issuer's revenues for its most recent fiscal year were approximately \$1,382,113.

The aggregate market value of the issuer's common stock, par value \$.0005 per share (the "Common Stock"), held by non-affiliates of the issuer as of June 29, 2005, based on the average of the closing bid and asked prices of \$0.285, for such shares on such date, was approximately \$7,200,000. For purposes of such calculation, shares of Common Stock held by each executive officer and director and by each person who owns more than 5% of the outstanding shares of Common Stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

The number of shares of the Common Stock outstanding as of June 29, 2005 was 53,882,037.

Documents Incorporated by Reference:

Not applicable.

Transitional Small Business Disclosure Format (check one): Yes [\_] No [X]

#### EXPLANATORY NOTE

This Amendment No. 2 on Form 10-KSB/A to the Annual Report on Form 10-KSB (the "Annual Report") of ADM Tronics Unlimited, Inc. (the "Company" or "ADM") filed with the Securities and Exchange Commission (the "SEC") on July 14, 2005 and amended on December 9, 2005, is filed to clarify the beneficial ownership of the securities of the Company and to resubmit the audit opinion of the Company's independent accountants which includes an additional paragraph regarding the restatement of the Company's financial statements. The Company is amending and restating in its entirety Item 7 of Part II and Item 11 of Part III of the Annual Report. Except as described above, no other amendments are being made to the Annual Report. This Form 10-KSB/A does not reflect events occurring after the July 14, 2005 filing of our Annual Report or modify or update the disclosure contained in the Annual Report in any way other than as required to reflect the amendments discussed above and reflected below.

Unless otherwise indicated in this prospectus, references to "we," "us," "our" or the "Company" refer to ADM Tronics Unlimited, Inc. and its subsidiaries.

Part II

Item 7. Financial Statements

> ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES MARCH 31, 2005

> > INDEX

Page No.

FINANCIAL STATEMENTS:

Report of Independent Registered Public Accounting Firm F-1

Consolidated Balance Sheet as of March 31, 2005

F-2

Consolidated Statements of Operations

For the Years Ended March 31, 2005 and 2004

F-3

Consolidated Statements of Changes in

Stockholders' Equity (Deficiency)

For the Years Ended March 31, 2005 and 2004

F-4

Consolidated Statements of Cash Flows

For the Years Ended March 31, 2005 and 2004

F-5

Notes to Consolidated Financial Statements

F-6/F-19

THE FOLLOWING REPORT IS A COPY OF A REPORT PREVIOUSLY ISSUED BY WEINICK SANDERS LEVENTHAL & CO., LLP AND HAS NOT BEEN REISSUED BY WEINICK SANDERS LEVENTHAL & CO., LLP.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Stockholders ADM Tronics Unlimited, Inc. and Subsidiaries Northvale, New Jersey

We have audited the accompanying consolidated balance sheet of ADM Tronics Unlimited, Inc. and subsidiaries as of March 31, 2005, and the related consolidated statements of operations, changes in stockholders' equity (deficiency), and cash flows for the years ended March 31, 2005 and 2004. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of ADM Tronics Unlimited, Inc. and subsidiaries as of March 31, 2005, and the results of their operations and their cash flows for the years ended March 31, 2005 and 2004, in conformity with United States generally accepted accounting principles.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a stockholders' deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Weinick Sanders Leventhal & Co., LLP

New York, New York July 13, 2005

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders ADM Tronics Unlimited, Inc. and Subsidiaries Northvale, New Jersey

We have audited the accompanying restated balance sheets of ADM Tronics Unlimited, Inc. and Subsidiaries as of March 31, 2005, and the related restated consolidated statements of operations, changes in stockholders' equity (deficiency), and cash flows for the year ended March 31, 2005. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of ADM Tronics Unlimited, Inc. and Subsidiaries as of March 31, 2005, and the results of their operations and their cash flows for the year ended March 31, 2005, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 1r to the financial statements, the March 31, 2005 financial statements have been restated primarily to record a beneficial conversion feature related to the Company's convertible notes payable and an additional discount related to the fair value of warrants issued with the debt.

The accompanying financial statements have been prepared assuming that the company will continue as a going concern. As discussed in note 2 to the financial statements, the company has suffered recurring losses from operations and has a stockholders deficiency that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Raich Ende Malter & Co. LLP

East Meadow, New York October 26, 2005

## CONSOLIDATED BALANCE SHEET MARCH 31, 2005 (RESTATED)

#### ASSETS

Current assets:	
Cash and cash equivalents	\$3,011,631
Accounts receivable - trade, less allowance	
for doubtful accounts of \$72,593 Inventories:	102,691
Raw materials and supplies	124,393
Finished goods	248,324
Prepaid expenses	283,048
Other current assets	36,248
Total current assets	\$3,806,335
Property and equipment - at cost, net of	
accumulated depreciation of \$271,188	40,550
Equipment in use and under lease agreements - at cost,	
net of accumulated depreciation of \$832,059	51 <b>,</b> 791
Inventory - long term portion	287,582
Loan receivable from officer, bearing interest	
at 3% per annum, unsecured	49,188
Deferred financing costs, net of accumulated amortization of \$127,644	823,564
amoreization of vizitori	023,001
Other assets	238,053
Total assets	\$5,297,063
Total assets	\$5,297,063 ======
	=======
Total assets  LIABILITIES AND STOCKHOLDERS' DEFICIENC	=======
LIABILITIES AND STOCKHOLDERS' DEFICIENCE Current liabilities:	Y
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:  Accounts payable	======= Y \$ 172,978
LIABILITIES AND STOCKHOLDERS' DEFICIENCE Current liabilities:	Y
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:  Accounts payable	======= Y \$ 172,978
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities  Total current liabilities	\$ 172,978 299,790
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities  Total current liabilities  Long-term debt:	\$ 172,978 299,790 \$ 472,768
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities  Total current liabilities  Long-term debt:    Warrants issued with registration rights	\$ 172,978 299,790 \$ 472,768
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,	\$ 172,978 299,790 \$ 472,768 1,449,326 6,087,500
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities  Total current liabilities  Long-term debt:    Warrants issued with registration rights	\$ 172,978 299,790 \$ 472,768
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,	\$ 172,978 299,790  \$ 472,768 1,449,326 6,087,500 (2,628,219)
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,    Discount on unsecured notes payable  Total long-term debt	\$ 172,978 299,790 \$ 472,768 1,449,326 6,087,500 (2,628,219)
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,    Discount on unsecured notes payable	\$ 172,978 299,790 \$ 472,768 1,449,326 6,087,500 (2,628,219)
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:     Accounts payable     Accrued expenses and other current liabilities      Total current liabilities  Long-term debt:     Warrants issued with registration rights     6% unsecured notes payable - long-term,     Discount on unsecured notes payable      Total long-term debt  Commitments and contingencies  Stockholders' deficiency:	\$ 172,978 299,790 \$ 472,768 1,449,326 6,087,500 (2,628,219)
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,    Discount on unsecured notes payable     Total long-term debt  Commitments and contingencies  Stockholders' deficiency:    Preferred stock, \$.01 par value, 5,000,000 shares	\$ 172,978 299,790 \$ 472,768 1,449,326 6,087,500 (2,628,219)
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,    Discount on unsecured notes payable     Total long-term debt  Commitments and contingencies  Stockholders' deficiency:    Preferred stock, \$.01 par value, 5,000,000 shares authorized	\$ 172,978 299,790 \$ 472,768 1,449,326 6,087,500 (2,628,219)
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,    Discount on unsecured notes payable     Total long-term debt  Commitments and contingencies  Stockholders' deficiency:    Preferred stock, \$.01 par value, 5,000,000 shares    authorized    Common stock, \$.0005 par value, 150,000,000 shares	\$ 172,978 299,790 \$ 472,768 1,449,326 6,087,500 (2,628,219) 4,908,607
LIABILITIES AND STOCKHOLDERS' DEFICIENCE  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,    Discount on unsecured notes payable     Total long-term debt  Commitments and contingencies  Stockholders' deficiency:    Preferred stock, \$.01 par value, 5,000,000 shares authorized	\$ 172,978 299,790 \$ 472,768 1,449,326 6,087,500 (2,628,219)
LIABILITIES AND STOCKHOLDERS' DEFICIENC  Current liabilities:    Accounts payable    Accrued expenses and other current liabilities     Total current liabilities  Long-term debt:    Warrants issued with registration rights    6% unsecured notes payable - long-term,    Discount on unsecured notes payable     Total long-term debt  Commitments and contingencies  Stockholders' deficiency:    Preferred stock, \$.01 par value, 5,000,000 shares authorized    Common stock, \$.0005 par value, 150,000,000 shares authorized; 53,882,037 shares issued and outstanding	\$ 172,978 299,790 

Accumulated deficit	(9,175,610)
Total stockholders' deficiency	( 84,312)
Total liabilities and stockholders' deficiency	\$5,297,063

See accompanying notes to consolidated financial statements.

F-2

## ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

For the Years Ended March 31,

Haren 31,		2005 (RESTATED)		2004
Revenues: Sales Rental income Other income (including interest income)	\$	955,438 330,636 96,039	\$	999,282 106,085 57,889
Total revenues		1,382,113	-	1,163,256
Costs and expenses:    Cost of sales    Depreciation and amortization of property and equipment and equipment in use and underlease agreements    Salaries and officer's compensation    Research and development    Write-off of investments    Selling, general and administrative    Interest expense    Amortization of debt discount    Change in fair value of warrant liability	∍r	139,213 609,365 270,894  2,048,935 154,756 180,052 581,749		528,569 146,717 189,569  52,259 379,780 8,100  
Total costs and expenses		4,515,836	-	1,304,994
Net loss	(\$	3,133,723)	(\$	141,738)
Weighted average number of common shares outstanding	!	52,548,704	51	1,007,037
Net loss per share, basic and diluted	(\$	0.06)	\$	0.00

See accompanying notes to consolidated financial statements.

# ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) FOR THE YEARS ENDED MARCH 31, 2005 and 2004 (Restated)

		Shares 0 150,000,0 d Authorize \$.0005 Pa	d r Par	Capital in Excess of Pa Value	ar Def'd Comp		Total
Balance at April 1, 2003	3	50,382,037	\$25 <b>,</b> 191	\$6,773,724	\$	(\$5,900,149)	\$898,766
Issuance of common stock		1,500,000	750	14,250			15,000
Valuation of 920,000 share	ces						
issued by subsidiary				73,600	(69,600)		4,000
Net loss						(141,738)	(141,738)
Balance March 31, 200	)4	51,882,037	25,941	6,861,574	(69,600)	(6,041,887)	776,028
Valuation of warrants issued to underwriter for services	5			67,253			67,253
Beneficial conversion feature					1,940,694		1,940,694
Issuance of warrants				294,761	(294,761)		
Issuance of warrants for placemer services	nt			208,690			208,690
Issuance of common stock	ς	2,000,000	1,000	19,000			20,000
Amortization deferred	of						

compensation			36,746		36,746
Net loss	 			(3,133,723) (	3,133,723)
Balance - March 31, 2005 As restated	 53,882,037	\$26,941	\$9,391,972	(\$327,615)(\$9,175,610)	(\$84,312)

See accompanying notes to consolidated financial statements.

F-4

## ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Years Ended			
	March 31,			
	2005	2004		
	(RESTATED)			
Cash flows from operating activities:				
Net loss	(\$3,133,723)	(\$ 141,738)		
Adjustments to reconcile net loss to net cash				
provided by (used in) operating activities:				
Depreciation and amortization	143,796	147,475		
Amortization of deferred financing costs	86,884			
Amortization of deferred compensation	36,746			
Stock based compensation	67,253			
Amortization of debt discount	180,052			
Change in fair value of warrant liability	581,749			
Issuance of common stock for services	20,000	14,250		
Other	19,148	11,000		
Write-off of investments		52,259		
Increase (decrease) in allowance for doubtful				
accounts	43,593	(10,000)		
Increase (decrease) in cash flows as a result				
of changes in asset and liabilities account				
balances:				
Accounts receivable - trade	(27,851)	(32,811)		
Inventories	(105,532)	25,402		
Other current assets	(286, 303)	1,096		
Equipment held for sale	56,883	16,056		
Other assets	(3,446)	4,946		
Accounts payable	13,180	(40,833)		
Accrued expenses and other current	,			
liabilities	248,450	(8,239)		
Total adjustments	1,074,602	180,601		
	_, ,			
Net cash provided by (used in) operating activities	(2,059,121)	38,863		
Cash flows from investing activities:				
Repayments of loans by officer		703		
Purchase of equipment, net	(46,594)			
Patent costs incurred	(49,612)			

Net cash provided by (used in) investing activities	(96,206)		703
Cash flows from financing activities:			
Issuance of common stock			750
Private placements costs incurred	(742,498)		
Registration costs incurred	(133, 125)		
Payment of note payable - estate of former			
officer/stockholder	(135,000)		
Proceeds from issuance of unsecured notes payable	6,087,500		
Net cash provided by financing activities	5,076,877		750
	0 001 550		40 016
Net increase in cash and cash equivalents	2,921,550		40,316
Cash and cash equivalents - beginning of year	90,081		49,765
Cash and cash equivalents - end of year	3,011,631	Ś	90,081
cash and cash equivarenes end of year	, 3,011,031	Ÿ	JO, 001
Supplemental information:			
Interest paid	105,890	\$	
Income taxes paid	3,414	\$	3,434
•			
Supplemental disclosure of non-cash operating			
and financing activities:			
Common stock and warrants issued as			
consideration for consulting services	449,000	\$	87 <b>,</b> 850

See accompanying notes to consolidated financial statements.

F-5

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED MARCH 31, 2005 and 2004

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES.

#### (a) Consolidation:

The consolidated financial statements include the accounts of ADM Tronics Unlimited, Inc. and its subsidiaries (the "Company"). All significant intercompany balances and transactions have been eliminated in consolidation.

#### (b) Business Activity:

The Company is a manufacturer and engineering concern whose principal lines of business are the production and sale of chemical products and manufacturing, selling and leasing of medical equipment and medical devices. The chemical product line is principally comprised of water-based chemical products used in the food packaging and converting industries. These products are sold to customers located in the United States, Australia, and Europe. Medical equipment is manufactured in accordance with customer specification on a contract basis. The medical device product line consists principally of proprietary devices used in the treatment of joint pain, postoperative edema, and tinnitus. These products are sold or leased to customers located in the United States and Asia.

For the years ended March 31, 2005 and 2004, the chemical product line accounted for approximately 68% and 80% of revenues and the medical device product line accounted for approximately 32% and 20%, respectively.

#### (c) Cash and Cash Equivalents:

The Company considers all highly-liquid investments with a remaining maturity of three months or less at the time of purchase and excess operating funds invested in cash management and money market accounts to be cash.

The Company places its cash and money market investments with high credit quality financial institutions. At times, such investments may be in excess of the FDIC insurance limit. At March 31, 2005, cash balances exceeded FDIC insurance limits by \$2,811,631.

#### (d) Inventories:

Inventories are stated at the lower of cost (first-in, first-out method) or market. Inventory that is expected to be sold within one operating cycle (1 year) is classified as a current asset. Inventory that is not expected to be sold within 1 year, based on historical trends, is classified as Inventory - long term.

#### (e) Property and Equipment:

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of 5 to 10 years. Leasehold improvements are amortized over the lease term or useful lives, whichever is shorter. Expenditures for major betterments and additions are charged to the asset accounts while replacements, maintenance and repairs, which do not improve or extend the lives of the respective assets, are charged to expense currently.

#### (f) Sonotron Devices:

Sonotron Devices ("Devices") are held for sale or lease and are included in the consolidated balance sheet under "Inventory - long term" and "Equipment in use and under lease agreements" on a specific identification basis. Unless and until clearance to market is obtained from the United States Food and Drug Administration (FDA), the Devices cannot be marketed in the United States for human applications, other than for research purposes, and may not be marketable in certain foreign countries.

F-7

#### NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. (Continued)

Included in equipment in use and under lease agreements are Devices used internally and Devices loaned out for marketing and testing. Devices in use and under lease agreements are depreciated over seven years commencing at the date placed in service. Revenues from leasing activities have not been significant.

#### (g) Sofpulse Units:

Sofpulse Units ("Units"), an FDA cleared device, are included in the consolidated balance sheet under "Equipment held for sale"

and "Equipment in use and under lease rental agreements," on a specific identification basis. Included in equipment in use and under lease agreements are Sofpulse Units leased to third parties, Units used internally and Units loaned out for marketing and testing. These Units are depreciated over seven years commencing on the date placed in service.

#### (h) Other Assets:

Patents and patents assigned are stated at cost and are included in other assets and are amortized on a straight-line basis over the shorter of their legal or useful lives (15 to 17 years for patents, and 2 years for patents assigned). Amortization expense is expected to be approximately \$10,000 in each of the succeeding five years.

Deferred financing costs of the private placement offering are being amortized through the five-year maturity dates of the related unsecured notes payable.

The valuation of deferred compensation related to subsidiary shares and warrants issued is being amortized over their respective vesting periods of 5 to 6 years for those shares and warrants.

#### (i) Long-lived Assets:

Long-lived assets, including intangibles, to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. If required, impairment losses on assets to be held and used are recognized based on the excess of the asset's carrying value over its fair value. Long-lived assets to be sold are reported at the lower of carrying amount or fair value reduced by estimated disposal costs.

The Company has adopted SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." The Company's adoption of SFAS No. 144 did not have an effect on the Company's results of operations, cash flows, or financial position.

#### (j) Revenue Recognition:

Sales revenues are recognized when products are shipped to end users and rental and lease revenues are recognized principally on either a monthly or a pay-per use basis in accordance with individual rental or lease agreements and are recognized on a monthly basis as earned. Shipments to distributors are recognized as sales where no right of return exists. This is generally the case with sales of chemicals. This is generally not the case with sales of the SofPulse units. The Company recognizes revenue from the sale of the SofPulse products when the products are shipped to end users. An increasing amount of rental revenue is recognized on a fixed monthly recurring basis as product is utilized by the end-user. Sales returns have been immaterial. Lease revenues through third party distributors have also been immaterial and there have been no sales through third party distributors. The Company's products are principally shipped on a "freight collect" basis. Shipping and handling charges and costs are immaterial.

F-8

Other income for the year ended March 31, 2005 consists of legal settlements of \$64,833, interest income of \$29,106 and miscellaneous income of \$2,100. For the year ended March 31, 2004 other income consists of office space rental and technical services of \$52,039, interest income of \$1,997 and miscellaneous income of \$3,853.

#### (k) Advertising:

Advertising (approximately \$138,000 and \$4,000 in 2005 and 2004, respectively) is expensed as incurred and is included with selling, general and administrative expenses in the consolidated statements of operations.

#### (1) Net Loss Per Share:

The Company applies Statement of Financial Accounting Standards No. 128, "Earnings Per Share" (FAS 128). Net loss per share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the reported periods. The assumed exercise of common stock equivalents was not utilized for the year ended March 31, 2005 since the effect would be anti-dilutive. There were 50,182,341 common stock equivalents at March 31, 2005 and none at March 31, 2004.

#### (m) Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### (n) Fair Value of Financial Instruments:

The carrying values of cash, cash equivalents, accrued expenses and notes payable approximate their fair values due to the maturity of these instruments, net of discount.

The fair value of the officer loan receivable is determined by calculating the present value of the note by a current market rate of interest as compared to the stated rate of interest. The difference between fair value and carrying value is not deemed to be significant.

#### (o) Basis of Presentation:

The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America.

#### (p) Minority Interest:

A subsidiary, Ivivi Technologies, Inc. ("Ivivi"), of the Company has a minority interest which owns 31.5% of that company.

Since the losses applicable to the minority interest in the Ivivi subsidiary exceed the minority interest in the equity capital

of the subsidiary, such excess and any further losses applicable to the minority interest are charged against the majority interest, as there is no obligation of the minority interest to make good such losses. However, if future earnings do materialize, the majority interest shall be credited to the extent of such losses previously absorbed.

#### (q) Research and Development Costs

Research and development costs are expensed as incurred.

#### (r) Restatement:

The March 31, 2005 financial statements have been restated to record a beneficial conversion feature related to the Company's convertible notes payable described in Note 3. The Company has also recorded an additional discount related to the fair value of warrants issued with the debt. The result is to increase the total discount on debt to \$2,808,271 from \$325,000. Also, the fair value of the warrants has been corrected to reflect a fair value of \$1,449,326 at March 31, 2005 as opposed to \$325,000 as previously reported.

Additionally, the Company issued compensation warrants related to the debt placement with a fair value of \$208,690 and has recorded deferred compensation of \$294,761 related to warrants issued for services. As a result of these corrections, net loss for the year ended March 31, 2005 has increased by \$809,310, to \$3,133,723, and loss per share has increased to \$0.06 from \$0.04.

Changes to the balance sheet at March 31, 2005 resulting from these corrections are as follows:

	As r	reported	Restated
Deferred financing costs	670,498	823,564	
Deferred compensation	106,880	327,615	
Unamortized debt discount	\$ 299,000	\$ 2,628,219	
Warrants issued with			
registration rights	325,000	1,449,326	
Capital in excess of par value	7,003,968	9,391,972	
Accumulated deficit	(8,366,300)	(9,175,610)	

The financial statements as at and for the year ended March 31, 2004 have been restated to reflect the fair market value of 920,000 shares of IVIVI's common stock issued in the fourth quarter of the fiscal year ended March 31, 2004 to officers, employees, and others in the amount of \$73,600, and \$4,000 additional amortization of the related deferred compensation for the year ended March 31, 2004.

F-9

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. (Continued)

#### (s) Trade Accounts Receivable

Trade accounts receivable are stated at the amount management expects to collect from outstanding balances. Management provides for probable uncollectible amounts through a charge to earnings and a credit to a valuation allowance based on its assessment of the current status of individual

accounts. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.

#### (t) Stock Options and Warrants

The Company accounts for its stock-based employee compensation plans using the intrinsic value based method, under which compensation cost is measured as the excess of the stock's market price at the grant date over the amount an employee must pay to acquire the stock. Stock options and warrants issued to non-employees are accounted for using the fair value based method, under which the expense is measured as the fair value of the security at the date of grant based on the Black-Scholes pricing model. A subsidiary of the Company had 578,500 employee stock options outstanding at March 31, 2005 and 2004.

#### Pro Forma Information

Employee and Director Common Share Purchase Options- Pro forma information regarding the effects on operations of employee and director common share purchase options as required by SFAS No. 123 and SFAS No. 148 has been determined as if the Company's subsidiary had accounted for those options under the fair value method. Pro forma information is computed using the Black Scholes method at the date of grant of the options based on the following assumptions ranges: (1) risk free interest rate of 3.62%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of our common stock of 67%; and (4) an expected life of the options of 6 years. The foregoing option valuation model requires input of highly subjective assumptions. Because common share purchase options granted to employees and directors have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value of estimates, the existing model does not in the opinion of our management necessarily provide a reliable single measure of the fair value of common share purchase options we have granted to our employees and directors.

Pro forma information relating to employee and director common share purchase options is as follows:

	Ende		r the Year Ended March 31, 2004
Net loss as reported Current period expense calculated under APB 25	\$(3,13	3,723)	\$ (141,738)
Stock compensation calculated			
under SFAS 123	(	9,966)	(12 <b>,</b> 458)
Pro forma net loss	\$(3,14	3,689)	\$ (154 <b>,</b> 196)
Historical basic and diluted			
loss per share	\$	(0.06)	\$ 0.00
Pro forma basic and diluted			
loss per share	\$	(0.06)	\$ 0.00

<sup>(</sup>u) New Accounting Pronouncements:

In December 2004, the FASB issued SFAS No.153, "Exchanges of Nonmonetary Assets, an amendment of APB Opinion No. 29, Accounting for Nonmonetary Transactions." The amendments made by Statement 153 are based on the principle that exchanges of nonmonetary assets should be measured based on the fair value of the assets exchanged. Further, the amendments eliminate the narrow exception for nonmonetary exchanges of similar productive assets and replace it with a broader exception for exchanges of nonmonetary assets that do not have commercial substance. Previously, Opinion 29 required that the accounting for an exchange of a productive asset for a similar productive asset or an equivalent interest in the same or similar productive asset should be based on the recorded amount of the asset relinquished. Opinion 29 provided an exception to its basic measurement principle (fair value) for exchanges of similar productive assets. The FASB believes that exception required that some nonmonetary exchanges, although commercially substantive, be recorded on a carryover basis. By focusing the exception on exchanges that lack commercial substance, the FASB believes this statement produces financial reporting that more faithfully represents the economics of the transactions. SFAS 153 is effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. Earlier application is permitted for nonmonetary asset exchanges occurring in fiscal periods beginning after the date of issuance. The provisions of SFAS 153 shall be applied prospectively. The Company has evaluated the impact of the adoption of SFAS 153, and does not believe the impact will be significant to the Company's overall results of operations or financial position.

In December 2004, the FASB issued SFAS No.123 (revised 2004), "Share-Based Payment". SFAS 123(R) will provide investors and other users of financial statements with more complete and neutral financial information by requiring that the compensation cost relating to share-based payment transactions be recognized in financial statements. That cost will be measured based on the fair value of the equity or liability instruments issued. SFAS 123(R) covers a wide range of share-based compensation arrangements including share options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans. SFAS 123(R) replaces FASB Statement No. 123, "Accounting for Stock-Based Compensation", and supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees". SFAS 123, as originally issued in 1995, established as preferable a fair-value-based method of accounting for share-based payment transactions with employees. However, that statement permitted entities the option of continuing to apply the guidance in Opinion 25, as long as the footnotes to financial statements disclosed what net income would have been had the preferable fair-value-based method been used. Public entities (other than those filing as small business issuers) will be required to apply SFAS 123(R) as of the first interim or annual reporting period that begins after June 15, 2005. SFAS 123(R) is applicable for the Company effective the first interim period that starts after December 15, 2005. The Company has evaluated the impact of the adoption of SFAS 123(R), and believes that the impact may be significant to the Company's overall results of operations and financial position (a pro forma effect, as estimated by management, is disclosed elsewhere in these notes).

In January 2003, the FASB issued FASB Interpretation No. ("FIN") 46, "Consolidation of Variable Interest Entities" ("FIN 46"). In December 2003, FIN 46 was replaced by FASB interpretation

No.  $46\,(R)$  "Consolidation of Variable Interest Entities." FIN  $46\,(R)$  clarifies the application of Accounting Research Bulletin No. 51, "Consolidated Financial Statements," to certain entities in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the

F-10

#### NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. (Continued)

entity to finance its activities without additional subordinated financial support from other parties. FIN 46(R) requires an enterprise to consolidate a variable interest entity if that enterprise will absorb a majority of the entity's expected losses, is entitled to receive a majority of the entity's expected residual returns, or both. FIN 46(R) is effective for entities being evaluated under FIN 46(R) for consolidation no later than the end of the first reporting period that ends after March 15, 2004. The Company does not currently have any variable interest entities that will be impacted by adoption of FIN 46(R).

#### NOTE 2 - CONTINUATION AS A GOING CONCERN.

The Company has had substantial net losses of \$3,133,723 and \$141,738 for the years ended March 31, 2005 and 2004, respectively. The Company has a stockholders' deficiency of \$84,312 at March 31, 2005. These factors raise substantial doubt about the ability to continue as a going concern. The significant increase in the net loss for the year ended March 31, 2005 is the result of expanded activities of Ivivi. In anticipation of expanding the Company's subsidiary operation, the Company raised \$6,087,500 in a private placement, (see Note 3), and at March 31, 2005 had cash and cash equivalents of \$3,011,631 and working capital of \$3,333,567.

The Company's net loss for the year ended March 31, 2005 has been principally funded from the net proceeds received from the Private Placement Offering of the 6% Unsecured Notes Payable (see Note 3).

The continuation of the Company as a going concern is dependent on the Company's ability to increase revenues, in receiving additional financing from outside sources including a public offering of stock of a subsidiary company, and a return to profitable operations. Management is pursuing a number of financing avenues for the subsidiary as well as attempting to secure ongoing revenue relationships for the subsidiary's products.

#### NOTE 3 - PRIVATE PLACEMENT FINANCINGS.

On December 1, 2004 and February 11, 2005, the Company completed private placement financings (collectively, the "Placements") to "accredited investors" only, consisting of an aggregate of \$6,087,500 aggregate principal amount of unsecured convertible notes bearing interest at an annual rate of 6%. The notes are due at various times from July 2009 through February 2010, unless converted earlier, and will convert automatically upon the consummation of a public offering into 733,434 shares of Ivivi's common stock, subject to adjustment, plus up to an additional 5,060 shares of Ivivi's common stock for the payment of interest on the notes through April 30, 2005 and 3,708 shares for each month

thereafter until the date that Ivivi files a registration statement with the Securities and Exchange Commission and the offering of its common stock is declared effective, assuming each holder elects to have their interest paid in shares of the Ivivi's common stock. Interest on the notes is payable quarterly in cash or shares of our common stock, at the direction of the holder. In addition, commencing March 1, 2005, with respect to the investors holding the notes issued in the private placement that was completed in December 2004, and June 30, 2005, with respect to the investors holding the notes issued in the private placement that was completed in February 2005, the investors will have the additional right to receive interest payments in shares of ADM Tronics common stock in lieu of cash or shares of the Ivivi's common stock. In connection with the

F-11

NOTE 3 - PRIVATE PLACEMENT FINANCINGS. (Continued)

issuance of the notes, Ivivi also issued to the investors warrants to purchase an aggregate of 733,434 shares of Ivivi's common stock at \$5.70 per share, as well as warrants to purchase an aggregate of 20,991,379 shares of the common stock of ADM Tronics at \$.41 per share. Warrants to purchase shares of ADM Tronic's common stock automatically expire upon the consummation of a public offering. Under the terms of the notes sold in the private placement that was completed in December 2004 and February 2005, the number of shares of the Ivivi's common stock issuable upon conversion of the notes and exercise of the warrants will increase by 2% for each 30-day period, or portion thereof, after March 1, 2005 and June 30, 2005, respectively, that the registration statement in connection to the public offering of Ivivi's common stock is not declared effective. As a result, as of April 30, 2005, an additional 17,530 shares of common stock underlying the notes and 17,530 shares underlying the warrants will be issuable by Ivivi. Based upon a Black Scholes Option Valuation Model, the value attributable to the warrants issued in the private placement through March 31, 2005 was \$2,031,075. Accordingly, the notes payable were discounted by \$2,808,271. The discount will be amortized over the term of the notes to their maturity date.

As additional consideration for the purchase of the notes, the Company granted to the purchasers warrants entitling them to purchase 20,991,379 common shares at the price of \$0.41 per share. These warrants lapse if unexercised after five years, or upon an effective registration statement of Ivivi. A registration rights agreement was executed requiring the Company to register the shares of its common stock underlying the notes and warrants so as to permit the public resale thereof. In accordance with EITF 00-27, a portion of the proceeds was allocated to the warrant liability based on its fair value, which totaled \$867,577 using the Black-Scholes option pricing model. The remaining balance was allocated to the convertible notes and was used to compute the beneficial conversion feature. The Company attributed a beneficial conversion feature of \$1,940,694 to the convertible notes based upon the difference between the effective conversion price of those shares and the closing price of the Company's common shares on the date of issuance. The assumptions used in the Black-Scholes model are as follows: (1) dividend yield of 0%; (2) expected volatility of 64%, (3) risk-free interest rate of 1.5%, and (4) expected life of six months. The total debt discount of \$2,808,271 is being amortized over the term of the notes. During the year ended March 31, 2005, amortization as interest expense amounted to 180,052.

Since the warrant is a contract requiring settlement through the delivery of registered shares, and the delivery of such registered shares was not deemed controllable by the Company, the Company recorded the net value of the

warrants at the date of issuance as a warrant liability on the balance sheet (\$867,577) and included the change in fair value from the date of issuance to March 31, 2005 in other income (expense), in accordance with EITF 00-19, "Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock". The fair value of the warrants was \$1,449,326 at March 31, 2005.

Upon a registration statement covering the underlying shares being declared effective, the fair value of the warrants on that date will be reclassified to equity.

Ivivi has filed a Registration Statement with the Securities and Exchange Commission for the issuance of a portion of its Common Stock.

NOTE 4 - PROPERTY AND EQUIPMENT.

Property and equipment at March 31, 2005 consist of the following:

Machinery and equipment	\$277 <b>,</b> 225
Office furniture and fixtures and equipment	34,513
	311,738
Less accumulated depreciation and amortization	271,188
	\$ 40,550

Depreciation and amortization on property and equipment for the years ended March 31, 2005 and 2004 aggregated \$7,722 and \$15,268, respectively.

F-12

NOTE 5 - EQUIPMENT IN USE AND UNDER LEASE AGREEMENTS.

Equipment in use and under lease  $% \left( 1\right) =0$  agreements at March 31, 2005 consist of the following:

Sofpulse Units	\$874 <b>,</b> 580
Other Units	9,270
	883,850
Less accumulated depreciation	832,059
	\$ 51,791
	=======

Depreciation of equipment in use and under lease agreements for the years ended March 31, 2005 and 2004 aggregated \$131,470 and \$126,965, respectively.

#### NOTE 6 - OTHER ASSETS.

Other assets at March 31, 2005 consist of the following:

Patents, net of accumulated amortization of \$68,227	\$ 91,320
Deferred registration costs of filings with the	
Securities and Exchange Commission by Ivivi	133,125
Other	13,608
	\$ 238,053

(a) The costs connected with the registration statement which is being filed with the SEC have been deferred. Such costs will be charged to Paid-In Capital if the Registration Statement becomes effective; otherwise, such costs will be charged to operations.

#### NOTE 7 - INCOME TAXES.

The differences between the income taxes and the amount computed by applying the federal statutory income tax rate of 34% to income before taxes are as follows:

Income taxes	\$	\$
Tax benefit at U.S. statutory rates Change in valuation allowance	\$1,066,000 (1,066,000)	(\$ 48,000) 48,000
	2005	2004

F-13

#### NOTE 7 - INCOME TAXES. (Continued)

At March 31, 2005, the Company had deferred tax assets of approximately \$2,753,000 resulting from net operating loss carryforwards. The deferred tax assets are offset by a valuation allowance in the amount of \$2,753,000.

A valuation allowance is recorded when management believes it is more likely than not that tax benefits will not be realized. The change in the valuation allowance was based upon the consistent application of management's valuation procedures and circumstances surrounding its future realization.

The Company and its subsidiaries file consolidated Federal income tax returns. As of March 31, 2005, the Company has consolidated net operating loss carryforwards of approximately \$6,883,000 that will expire during the years 2006 through 2024.

#### NOTE 8 - EMPLOYEE BENEFIT PLAN.

The Company has a 401(k) Plan covering substantially all

employees. Employer matching contributions to the plan are at the discretion of management. There were no employer contributions to the plan for the years ended March 31, 2005 and 2004.

#### NOTE 9 - COMMITMENTS AND CONTINGENCIES.

#### (a) Leases:

The Company leases its office and manufacturing facilities under non-cancelable operating leases.

The approximate future minimum annual rental under these leases at March 31, 2005 are as follows:

Years En	ding:	
March 31,	2006	\$ 85,
March 31,	2007	85,
March 31,	2008	85,
March 31,	2009	22,
		\$277 <b>,</b>

Other leases are month-to-month.

Rent expense for all facilities for the years ended March 31, 2005 and 2004 was approximately \$127,000 and \$92,000, respectively.

#### (b) Warranties:

The Company's medical devices are sold under agreements providing for the repair or replacement of any devices in need of repair, at the Company's cost, for up to one year from the date of delivery, unless such need was caused by misuse or abuse of the device.

At March 31, 2005, no amount has been accrued for potential warranty costs and such costs are expected to be nominal.

#### (c) Legal Matters:

i. The Company is involved, from time to time, in litigation and proceedings arising out of the ordinary course of business. There are no pending material legal proceedings or environmental investigations to which the Company is a party or to which the property of the Company is subject.

F-14

#### NOTE 9 - COMMITMENTS AND CONTINGENCIES. (Continued)

ii. On May 25, 2005, Ivivi filed a lawsuit against an unrelated company and certain individuals. The complaint alleges that certain of Ivivi's confidential information was disseminated by the individuals to the other company. Ivivi is seeking injunctive relief enjoining the other company, its agents and employees for preliminary and permanent injunctions for compensatory and punitive damages, for an accounting and for

attorney's fees and costs.

Ivivi has filed a patent infringement suit against the other company to protect its proprietary interests. Legal counsel for the other company advised that several documents were forwarded to intellectual property counsel of the other company related to the filing of a patent infringement suit against ADM Tronics and its subsidiaries. Based upon the foregoing, there is the possibility of litigation and counterclaims. It is certainly possible and would not be unexpected for the other company to file a counterclaim against Ivivi.

iii. On April 30, 2004, the Company entered into a termination agreement with a lessor of some of the SofPulse Units. The lessor agreed to pay the Company \$85,000 and return the rental units that were leased. In the opinion of management, the agreement's termination did not have a material adverse effect on rental income of the Company.

The Company believes that the ultimate resolution of the foregoing matters will not have a material adverse impact on the Company's cash flows, financial condition or results of operations.

#### (d) Contractual Agreements:

- i. On September 9, 2004 and on October 17, 2004, Ivivi entered into Sponsored Research Agreements with the Montefiore Medical Center ("Montefiore"). Both agreements support research at Montefiore in areas related to Ivivi's fields of interest. The agreement dated September 9, 2004, is for a period of one year and the committed funding amount is \$28,750. The agreement dated October 17, 2004 remains in effect until December 31, 2009 and the committed funding amount is \$495,685. The research and development costs are being expensed over a one year period from inception of the agreements.
- ii. Effective January 1, 2004, Ivivi entered into a Consulting Agreement with the Chairman of the department of Plastic Surgery at Montefiore Medical Center pursuant to which Ivivi engaged the consultant to render consulting services to it for a term of six years with automatic one-year renewals. Pursuant to the consulting agreement, the consultant serves as Medical Director and Chairman of Ivivi's Medical Advisory Board and advises Ivivi on technological developments, future clinical and research applications and product development and efficacy in the pulsed magnetic frequencies field.

In exchange for the consultant's consulting services, the consultant received 80,000 shares of Ivivi's common stock, 10,000 of which vested immediately upon the Company's entering into the consulting agreement with him, 17.5% of which vested on January 5, 2005 and the remaining 70% of which shall vest in three equal yearly installments on January 5 of each year from January 5, 2006 through January 1, 2009. In addition, Ivivi has agreed to pay the consultant an annual bonus (not to

NOTE 9 - COMMITMENTS AND CONTINGENCIES. (Continued)

(d) Contractual Agreements: (Continued)

exceed \$500,000) equal to the sum of 0.5% of that portion of Ivivi's annual revenues in excess of \$20 million and up to \$80 million, 0.25% of that portion of Ivivi's annual revenues in excess of \$120 million. Ivivi has also agreed to pay the consultant a royalty equal to 0.05% of revenues received for practicing and/or commercializing any "new inventions" (as such term is defined in the agreement) developed by the consultant under the agreement. Bonuses and royalties payable for the fiscal years ended March 31, 2006 and 2007 are subject to a cap of 10% of Ivivi's pre-tax profit (after deduction of such bonuses and royalty payments) for such fiscal years. Bonuses and royalties payable under the consulting agreement are also subject to certain adjustments for returns, allowances or setoffs, to the consultant's compliance with the non-compete provisions of Ivivi's consulting agreement and certain other restrictions.

iii. On April 1, 2005, Ivivi entered into an agreement with Global Medical LLC in which Global will provide certain management services in regard to medical devices and products manufactured, distributed, sold or rented by Ivivi. The term of the agreement commences October 1, 2005 for a two year period during which Global will be paid a monthly fee of \$45,000 and earn a certain percentage of each sale or rental Global makes of Ivivi's products. During the term of the agreement, Ivivi has the right to purchase some or all of the assets of Global utilized in the performance of the management services in exchange for Ivivi's assumption of certain on-going salary obligations of Global and Ivivi's issuance of equity securities to Global.

#### (e) Other:

The Centers for Medicare and Medicaid Services have issued a National Coverage Determination (NCD) providing coverage for the use of the Company's SofPulse medical device for treatment of wounds. The issuance of the NCD enables nursing homes, hospitals, physicians and rehabilitation clinics to obtain reimbursement for treatment of chronic, non-healing wounds with the Company's SofPulse medical devices.

#### NOTE 10 - STOCKHOLDERS' EQUITY.

#### (a) Stock Options and Warrants:

From time to time, the Company grants stock options to directors, officers and outside consultants.

A summary of the Company's stock option activity and related information for the years ended March 31, 2005 and 2004 is as follows:

F-16

#### NOTE 10 - STOCKHOLDERS' EQUITY. (Continued)

#### (a) Stock Options and Warrants: (Continued)

	Year Ended		Year Ended	
	March 31	1, 2005	March 31	, 2004
	Weight	ced	Weig	hted
	Average		Average	
	Exercise		Exercise	
	Options	Price	Options	Price
Outstanding at beginning				
of year		\$	5,192,819	\$ 0.2927
Granted	29,190,962	\$0.39		
Expired			(5,192,819)	\$(0.2927)
Outstanding at end				
of year	29,190,962	\$0.39		
Exercisable at end				
of year	29,190,962	\$0.39		

IVIVI has instituted a stock option plan for the issuance of 1,500,000 shares. As of March 31, 2005 and 2004, 751,200 and 686,500, respectively, options were awarded, with 748,800 reserved for future issuance. The option holder, upon receiving the grant is immediately vested in 20% of the grant and the option holder earns a continuing vesting right of the remaining balance for each of the next four years of service with IVIVI. The options have exercise prices ranging from \$.10 to \$10.00.

F-17

#### NOTE 10 - STOCKHOLDERS' EQUITY. (Continued)

#### (b) Common Stock:

In November 2003, a consulting company provided services to the Company valued at \$15,000 and acquired 1,500,000 non-registered common shares of the Company.

In January 2004, a group of individuals provided services valued at \$73,600 for IVIVI and received 920,000 common shares of

Ivivi, approximately 31.5% of the subsidiary's common stock. The valuation of the shares is being amortized over a five year vesting period with the fair market value having been credited to paid-in capital.

In December 2004, a consulting company provided services to the Company valued at \$20,000 and acquired 2,000,000 non-registered common shares of the Company.

## NOTE 11 - SEGMENT INFORMATION, GEOGRAPHICAL INFORMATION, MAJOR CUSTOMERS, AND CREDIT CONCENTRATION.

#### (a) Segment Information:

The Company adopted the provisions of SFAS No. 131, "Disclosures about Segments of an Enterprise and Related Information" effective April 1, 1999. The Company operates in two reportable segments, the production and sale of chemicals and the manufacture and sale or lease of medical products. The reportable segments are strategic business units that offer different products and services. They are managed separately based on differences in customer base, marketing strategies or regulatory environment.

The accounting policies of the segments are the same as those described in Note 1. The Company evaluates  $% \left( 1\right) =\left( 1\right) +\left( 1\right) +\left$ 

Information about segment operations follows:

Year Ended March 31, 2005	Chemical	Medical	Total
Revenues	\$ 876,679	\$ 409,395	\$ 1,286,074
Interest income	4,161	24,945	29,106
Interest expense	1,228	153,528	154 <b>,</b> 756
Depreciation and amortization	8,304	130,909	139,213
Segment income (loss)	96 <b>,</b> 537	(3,230,260)	(3,133,723)
Segment assets	934,382	4,362,681	5,297,063
Capital expenditures		46,594	46,594
Year Ended March 31, 2004	Chemical	Medical	Total
Revenues	\$ 887,312	\$ 218,055	\$ 1,105,367
Interest income	1,997		1,997
Interest expense	8,100		8,100
Depreciation and amortization	12,661	134,056	146,717
Segment loss	101,747	(224,760)	(141,738)
Segment assets	647,202	500,358	1,147,560

MAJOR CUSTOMERS, AND CREDIT CONCENTRATION.

#### (b) Geographical Information:

Sales and rentals to unaffiliated customers, based on location of customer, is as follows:

	Years E 2005	Inded March 31, 2004
Chemical Segment:		
United States	\$797 <b>,</b> 020	\$813,273
Foreign countries	79 <b>,</b> 659	74,039
	\$876 <b>,</b> 679	\$887,312
	=======	======
Medical Segment:		
United States	\$338 <b>,</b> 058	\$110 <b>,</b> 974
Asia	71,337	100,579
Other foreign countries		6,502
	\$409 <b>,</b> 395	\$218,055
	=======	=======

#### (c) Major Customers:

Sales to individual unaffiliated customers in excess of 10% of net sales to unaffiliated customers are shown below.

	Years 2005	Ended March 31, 2004
Chemical Segment:		
Customer A	\$271 <b>,</b> 124	\$255 <b>,</b> 254
	=======	=======
Customer B	\$144,831	\$169 <b>,</b> 281
	=======	=======
Medical Segment	\$	\$
	=======	=======

F-19

#### Part III

Item 11. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth information regarding ownership of shares of Company's common stock, as of June 29, 2005, by (i) each person known to the Company to be the owner of 5% or more of the Company's common stock (ii) each director and director nominee of the Company, (iii) each Named Officer, and (iv) all directors and officers of the Company as a group. Except as otherwise indicated, each person and each group shown in the table has sole voting and investment power with respect to the shares of the Company's common stock indicated. For purposes of the table below, in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, a person is

deemed to be the beneficial owner, for purposes of any shares of Common Stock over which he or she has or shares, directly or indirectly, voting or investment power; or of which he or she has the right to acquire beneficial ownership at any time within 60 days after June 29, 2005. As used herein, "voting power" is the power to vote or direct the voting of shares and "investment power" includes the power to dispose or direct the disposition of shares. Common Stock beneficially owned and percentage ownership is based on 53,882,037 shares of Common Stock outstanding as of June 29, 2005.

Name and Address		er of Sha icially C	ares Owned	Percentage
Andre' Di Mino c/o ADM Tronics Unlimited, 224-S Pegasus Ave. Northvale, NJ 07647		856,935(1	.)	38.7%
Vincent Di Mino c/o ADM Tronics Unlimited, 224-S Pegasus Ave. Northvale, NJ 07647	•	987,928 (	(2)	13.0%
David Saloff c/o ADM Tronics Unlimited, 224-S Pegasus Ave. Northvale, NJ 07647	Inc.	0		0.0%
Eugene Stricker c/o Fifth Avenue Venture Capital Partners 42 Barrett Road Lawrence, NY 11559	4,	250,000 (	(3)	7.9%
Heiko H. Thieme 1370 Ave of the Americas New York, NY 10019	3,	617,500 (	(4)	6.7%
Burton Friedlander 104 Field point Road. Greenwich, CT 06830	3,	313,900 (	(5)	6.2%
All Executive Officers and Directors as a group (three persons)	27,	844,863 (	(6)	51.7%

<sup>(1)</sup> Includes (i) 9,172,696 shares of the Company's common stock directly owned by Andre Di Mino; (ii) 1,700,000 shares of the Company's common stock held by the Andre' Di Mino Irrevocable Trust, a Trustee and the beneficiary of which is Andre' Di Mino, who may be deemed to be a beneficial owner of such shares; (iii) 1,700,000 shares of the Company's common stock held by the Maria Elena Di Mino Trust, a Trustee of which is Andre' Di Mino, who may be deemed to be a beneficial owner of such shares by reason of his power to vote such shares; (iv) 1,700,000 shares of the Company's common stock held by the Maurice Di Mino Irrevocable Trust, a Trustee of which is Andre' Di Mino, who may be deemed to be a beneficial owner of such shares by reason of his power to vote such shares; (v) 1,004,239 shares of the Company's common stock, which are held by the Estate of Dr. Alfonso Di Mino (the "Di Mino Estate"), the administrator of which is Andre' Di Mino who may be deemed to be a beneficial

owner of such shares by reason of his power to vote such shares, and of which Andre Di Mino, as a beneficiary of the Di Mino Estate, is entitled to receive 167,374 shares; (vi) 1,330,000 shares of the Company's common stock, which the Di Mino Estate has the power to vote pursuant to an agreement dated July 8, 1987, and with respect to which Andre' Di Mino may be deemed to be a beneficial owner by reason of his power to vote such shares in his capacity as administrator of the Di Mino Estate; and (vii) 4,250,000 shares of the Company's common stock held by Eugene Stricker, of which Andre' Di Mino may be deemed to be a beneficial owner by reason of his power to vote such shares pursuant to an agreement between Andre' DiMino and Eugene Stricker.

- (2) Includes 1,287,928 shares of the Company's common stock directly owned by Mr. Vincent Di Mino, 300,000 shares of the Company's common stock owned by the spouse of Vincent Di Mino, as to which Mr. Di Mino disclaims beneficial ownership; 300,000 shares of the Company's common stock owned by a child of Mr. Di Mino, who resides in Mr. Di Mino's home, as to which Mr. Di Mino disclaims beneficial ownership; and 5,100,000 shares of the Company's common stock of which 1,700,000 shares are held by each of the Andre' Di Mino Irrevocable Trust, the Maria Elena Di Mino Irrevocable Trust and the Maurice Di Mino Irrevocable Trust, a Trustee of which is Vincent Di Mino, who may be deemed to be a beneficial owner of the shares held by such trusts by reason of his power to vote such shares.
- (3) Mr. Di Mino may be deemed to be a beneficial owner of such shares by reason of his power to vote such shares pursuant to an agreement between Andre' DiMino and Eugene Stricker. Reference is also made to Footnote No. 1.
- (4) Includes 2,000,000 shares of the Company's common stock owned by The American Heritage Fund, Inc. and 1,617,500 shares of the Company's common stock Owned by The Global Opportunity Fund Limited, each of which Mr. Thieme is a principal.
- (5) Includes 2,896,600 shares of the Company's common stock owned by Friedlander International Limited, of which Mr. Friedlander is a principal.
- (6) Reference is made to Footnote Nos. 1 and 2.

#### Item 13. Exhibits

#### Exhibit

No. Description

- 3.1 Certificate of Incorporation and amendments thereto filed on August 9, 1976 and May 15, 1978 is incorporated by reference to Exhibit 3(a) to the Company's Registration Statement Form 10 (File No. 0-17629) (the "Form 10").
- 3.2 Certificate of Amendment to Certificate of Incorporation filed December 9, 1996 is incorporated by reference to Exhibit 3(a) to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1997.
- 3.3 By-Laws are incorporated by reference to Exhibit 3(b) to the Form 10.
- 4.1 Warrant issued to the Global Opportunity Fund Inc. is incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1998.
- 4.2 Warrant issued to Heiko H. Thieme is incorporated by reference to Exhibit 4.2 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1999.
- 4.3 Form of Company Warrant issued to certain investors (one in a series of warrants with identical terms) is incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K dated February 11, 2005
- 4.4 Form of Ivivi Warrant issued to certain investors (one in a series of

warrants with identical terms) is incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K dated February 11, 2005

- 4.5 Form of Note issued to certain investors (one in a series of notes with identical terms) is incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K dated February 14, 2005.
- 9.1 Trust Agreements of November 7, 1980 by and between Dr. Alfonso Di Mino et al. are incorporated by reference to Exhibit 9 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1993.
- 10.1 Memorandum of Lease by and between the Company and Cresskill Industrial Park III dated as of August 26, 1993 is hereby incorporated by reference to Exhibit 10(a) to the Company's Annual Report on Form 10-KSB for the fiscal year March 31, 1994.
- 10.2 Agreement of July 8, 1987 by and between Donna Di Mino, Dr. Alfonso Di Mino, et al. is hereby incorporated by reference to Exhibit 10(q) to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1993.
- 10.3 Agreement of March 21, 2002 by and between the Company and New England Acquisitions, Inc. is hereby incorporated by reference to Exhibit 10.8 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2002.
- 10.4 Agreement of April 29, 2003 by and between Vet-Sonotron Systems, Inc. and THM Group, LLC is hereby incorporated by reference the Exhibit 10.4 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2003.
- 10.5 Agreement of January 17, 2003 by and between the Company and Fifth Avenue Venture Capital Partners is hereby incorporated by reference to Exhibit 10.5 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2003.
- 10.6 Amended and Restated Manufacturing Agreement, dated February 10, 2005, among the Company, Ivivi Technologies, Inc. and Sonotron Medical Systems, Inc. is incorporated by reference to Exhibit 10.6 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005.
- 10.7 Management Services Agreement, dated August 15, 2001, among the Company, Ivivi Technologies, Inc., Sonotron Medical Systems, Inc. and Pegasus Laboratories, Inc., as amended, is incorporated by reference to Exhibit 10.7 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005.
- 10.8 Agreement of April 3, 2004 by and between the Company and Carepoint Group is incorporated by reference to Exhibit 10.6 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2004.
- 10.9 Placement Agency Agreement of May 20, 2004 by and between the Company and Maxim Group LLC. is incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated December 1, 2005.
- 10.10 Agreement of April 1, 2005 by and between Ivivi Technologies, Inc. and Global Medical, L.L.C. is incorporated by reference to Exhibit 10.10 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005.
- 14.1 Code of Ethics is incorporated by reference to Exhibit 14.1 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005.
- 21.1 Subsidiaries of the Company is incorporated by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005.
- 31.1 Certification of the Chief Executive Officer of the Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of the Chief Financial Officer of the Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of the Chief Executive Officer and Chief Financial Officer of the Company pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 99.1 Risk Factors is incorporated by reference to Exhibit 99.1 to the Company's Annual Report on Form 10-KSB/A for the fiscal year ended March 31, 2005.

#### SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused the amendment to this report to be signed on its behalf by the undersigned, thereunto duly authorized this 27th day of January, 2006.

ADM TRONICS UNLIMITED, INC.

By: /s/ Andre' DiMino
Andre' Di Mino
Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Andre' DiMino Andre' Di Mino	Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) and Director	January 27, 2006
/s/ Vincent Di Mino Vincent Di Mino	Director	January 27, 2006
/s/ David Saloff David Saloff	Director	January 27, 2006